semaglutide studies 2024 Impressive Results Alert! 📊🚀 show an average weight loss of 15% of body weight with use, which is significantly higher than most other weight loss medications. That's right Semaglutide Market Size, Share, Growth

Presented for research literature review only Zhang XN et al

The OpenLoop Affiliated Covered Entity includes OpenLoop Healthcare Partners PC, Rezilient OLH PA, and OpenLoop Healthcare Partners California PC

(average results) Wegovy (semaglutide) GLP-1 only In the STEP-1 study (68 weeks), average weight change was about: 14.9% with Wegovy 2.4% with placebo (dummy injection) What that looks like: If you start at 100 kg , 14.9% is about 15 kg lost on average

Its ability to help patients lose weight sparked caused a rush of demand and, subsequently, supply issues

Ewen MacDonald for checking the language of the manuscript

While branded products undergo the full FDA approval process with Phase I through Phase III clinical trials, compounded versions operate under a different regulatory framework